Net Sales are expected to increase by 2.8 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 550 crore, according to HDFC Securities.
HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Laurus Labs to report net profit at Rs. 30 crore down 46.7% year-on-year (up 57% quarter-on-quarter).
Net Sales are expected to increase by 2.8 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 550 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 17.4 percent Y-o-Y (up 15.5 percent Q-o-Q) to Rs. 90 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
